Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of Donepezil From Single Dose of GB-5001 IM Depot and Aricept® Oral Tablets in Healthy Male Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 26, 2022

Primary Completion Date

June 2, 2023

Study Completion Date

June 2, 2023

Conditions

Alzheimer Disease

Interventions

DRUG

GB-5001

Depending on the cohort, volume will be varied to administer.

DRUG

Placebo

A matched volume of placebo product will be administered to each subject in each cohort.

DRUG

Oral cohort

Single dose of Aricept tablet

Trial Locations (1)

Syneos Health, Québec

All Listed Sponsors

lead

G2GBio, Inc.

INDUSTRY